Literature DB >> 21606053

In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior?

Michael J Hughes1, Mohammed F Chowdhry, Steve M Woolley, William S Walker.   

Abstract

A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior?' Altogether 845 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that in stage I tumours there is little difference in survival when performing either mediastinal lymph node dissection (MLND) or lymph node sampling. However, survival is increased when performing MLND in stage II to IIIa tumours. Increased accuracy in staging is not observed with MLND. However, MLND reliably identifies more positive N2 nodes which may offer advantages in postoperative adjuvant treatment in more advanced disease.

Entities:  

Mesh:

Year:  2011        PMID: 21606053     DOI: 10.1510/icvts.2011.268979

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

1.  Transection of the arterial ligament for extended mediastinal lymph node dissection by video-assisted thoracoscopic surgery: invaluable technique for the right patient.

Authors:  Peter T White; Mara B Antonoff
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

2.  Evaluation of the necessity of Pulmonary Ligament Lymph Node Dissection for Upper Lobe Stage IB NSCLC: A Propensity Score-matched Study.

Authors:  Feng Wang; Xiangyang Yu; Yi Han; Lanjun Zhang; Shuku Liu
Journal:  J Cancer       Date:  2022-09-06       Impact factor: 4.478

3.  Nodal involvement pattern in resectable lung cancer according to tumor location.

Authors:  Somcharoen Saeteng; Apichat Tantraworasin; Juntima Euathrongchit; Nirush Lertprasertsuke; Yutthaphun Wannasopha
Journal:  Cancer Manag Res       Date:  2012-06-07       Impact factor: 3.989

4.  A nomogram for the prediction of overall survival in patients with stage II and III non-small cell lung cancer using a population-based study.

Authors:  Yi Liao; Xue Wang; Ping Zhong; Guofang Yin; Xianming Fan; Chengliang Huang
Journal:  Oncol Lett       Date:  2019-10-10       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.